PL2501406T3 - Biosyntetyczny układ wytwarzający immunogenne polisacharydy w komórkach prokariotycznych - Google Patents

Biosyntetyczny układ wytwarzający immunogenne polisacharydy w komórkach prokariotycznych

Info

Publication number
PL2501406T3
PL2501406T3 PL10831896T PL10831896T PL2501406T3 PL 2501406 T3 PL2501406 T3 PL 2501406T3 PL 10831896 T PL10831896 T PL 10831896T PL 10831896 T PL10831896 T PL 10831896T PL 2501406 T3 PL2501406 T3 PL 2501406T3
Authority
PL
Poland
Prior art keywords
prokaryotic cells
biosynthetic system
immunogenic polysaccharides
produces immunogenic
produces
Prior art date
Application number
PL10831896T
Other languages
English (en)
Polish (pl)
Inventor
Michael Wacker
Charles Waechter
Original Assignee
Glaxosmithkline Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals S.A. filed Critical Glaxosmithkline Biologicals S.A.
Publication of PL2501406T3 publication Critical patent/PL2501406T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/025Enterobacteriales, e.g. Enterobacter
    • A61K39/0258Escherichia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/025Enterobacteriales, e.g. Enterobacter
    • A61K39/0283Shigella
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/385Haptens or antigens, bound to carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6068Other bacterial proteins, e.g. OMP
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
PL10831896T 2009-11-19 2010-11-16 Biosyntetyczny układ wytwarzający immunogenne polisacharydy w komórkach prokariotycznych PL2501406T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27293109P 2009-11-19 2009-11-19
PCT/US2010/002980 WO2011062615A1 (en) 2009-11-19 2010-11-16 Biosynthetic system that produces immunogenic polysaccharides in prokaryotic cells
EP10831896.5A EP2501406B8 (en) 2009-11-19 2010-11-16 Biosynthetic system that produces immunogenic polysaccharides in prokaryotic cells

Publications (1)

Publication Number Publication Date
PL2501406T3 true PL2501406T3 (pl) 2018-05-30

Family

ID=44059888

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10831896T PL2501406T3 (pl) 2009-11-19 2010-11-16 Biosyntetyczny układ wytwarzający immunogenne polisacharydy w komórkach prokariotycznych

Country Status (20)

Country Link
US (2) US8846342B2 (https=)
EP (1) EP2501406B8 (https=)
JP (2) JP5968784B2 (https=)
KR (1) KR101855380B1 (https=)
CN (1) CN102724997B (https=)
AU (1) AU2010322454B2 (https=)
CA (1) CA2780487C (https=)
CY (1) CY1119995T1 (https=)
DK (1) DK2501406T3 (https=)
ES (1) ES2660227T3 (https=)
HR (1) HRP20180338T1 (https=)
HU (1) HUE038456T2 (https=)
IL (1) IL219733A (https=)
LT (1) LT2501406T (https=)
NO (1) NO2501406T3 (https=)
PL (1) PL2501406T3 (https=)
PT (1) PT2501406T (https=)
SI (1) SI2501406T1 (https=)
TR (1) TR201803015T4 (https=)
WO (1) WO2011062615A1 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL163806A0 (en) * 2002-03-07 2005-12-18 Eidgenoess Tech Hochschule System and method for the production of recombinant glycosylated proteins in a prokaryotic host
NO2501406T3 (https=) * 2009-11-19 2018-05-19
CA2844831A1 (en) 2011-08-12 2013-02-21 The Governors Of The University Of Alberta Method of diagnosing bacterial infections using bacterial glycoproteins
US9777076B2 (en) 2012-07-16 2017-10-03 Pfizer Inc. Saccharides and uses thereof
US20150353940A1 (en) * 2013-08-05 2015-12-10 Absci, Llc Vectors for use in an inducible coexpression system
EP2724730A1 (en) 2012-10-29 2014-04-30 Institut Pasteur Glycoconjugates and their use as potential vaccines against infection by Shigella Flexneri
PL2945651T3 (pl) 2013-01-17 2018-08-31 Arsanis Biosciences Gmbh Przeciwciało swoiste wobec E.coli MDR
GB201301085D0 (en) * 2013-01-22 2013-03-06 London School Hygiene & Tropical Medicine Glycoconjugate Vaccine
MX371513B (es) 2013-10-11 2020-01-31 Glaxosmithkline Biologicals Sa Metodos de modificacion de celulas huespedes.
WO2015124769A1 (en) 2014-02-24 2015-08-27 Glycovaxyn Ag Novel polysaccharide and uses thereof
CA2945542C (en) * 2014-04-17 2024-03-05 Glycovaxyn Ag Modified host cells and uses thereof
KR101629656B1 (ko) * 2014-10-24 2016-06-14 충남대학교산학협력단 면역증강효과를 갖는 수용성 다당체 및 이를 함유하는 조성물
CN107614679B (zh) * 2014-12-30 2026-04-07 葛兰素史密丝克莱恩生物有限公司 用于蛋白糖基化的组合物和方法
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
GB201518668D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition
CA3006400A1 (en) 2015-11-30 2017-06-08 Limmatech Biologics Ag Methods of producing glycosylated proteins
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
AR109621A1 (es) 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
GB201711635D0 (en) 2017-07-19 2017-08-30 Glaxosmithkline Biologicals Sa Immunogenic composition
GB201721576D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof
GB201721582D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions
CN113227125A (zh) 2018-12-12 2021-08-06 葛兰素史密丝克莱恩生物有限公司 用于o-连接的糖基化的修饰的载体蛋白
IL286467B2 (en) 2019-03-18 2026-02-01 Janssen Pharmaceuticals Inc Methods for producing bioconjugates of polysaccharides E. coli o-antigen, preparations thereof and methods for using them
CA3134216A1 (en) 2019-03-18 2020-09-24 Janssen Pharmaceuticals, Inc. Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof
EP3770269A1 (en) 2019-07-23 2021-01-27 GlaxoSmithKline Biologicals S.A. Quantification of bioconjugate glycosylation
WO2021255684A1 (en) 2020-06-18 2021-12-23 Glaxosmithkline Biologicals Sa Shigella-tetravalent (shigella4v) bioconjugate
WO2021259743A2 (en) 2020-06-25 2021-12-30 Glaxosmithkline Biologicals Sa Vaccine
AU2021342797B2 (en) 2020-09-17 2024-02-08 Janssen Pharmaceuticals, Inc. Multivalent vaccine compositions and uses thereof
CN112877246B (zh) * 2021-02-23 2022-01-18 山东省滨州畜牧兽医研究院 一种高效制备霍乱弧菌菌影的方法
CN115747239A (zh) * 2021-09-03 2023-03-07 上海交通大学 用于表达黏蛋白型o-糖基化蛋白的原核载体和系统、黏蛋白型o-糖基化蛋白的制备方法
WO2023118033A1 (en) 2021-12-22 2023-06-29 Glaxosmithkline Biologicals Sa Vaccine
GB202302579D0 (en) 2023-02-23 2023-04-12 Glaxosmithkline Biologicals Sa Immunogenic composition
WO2025172892A1 (en) 2024-02-16 2025-08-21 Glaxosmithkline Biologicals Sa Modified proteins and methods

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60142915A (ja) * 1983-12-28 1985-07-29 Lion Corp 口腔用組成物
ATE67786T1 (de) 1984-08-01 1991-10-15 Boehringer Ingelheim Int Neue genetische sequenzen, die durch sie codierten interferon-peptide vom typ i und diese sie produzierende organismen.
US5242809A (en) * 1986-02-28 1993-09-07 Smithkline Beecham Corporation Gal operon of streptomyces
US5643758A (en) 1987-03-10 1997-07-01 New England Biolabs, Inc. Production and purification of a protein fused to a binding protein
US5665559A (en) * 1989-05-18 1997-09-09 The United States Of America As Represented By The Secretary Of The Navy Production of monoclonal antibodies to bacteroides gingivalis by hybridoma BGII, VF9/2D
US5280113A (en) * 1989-08-16 1994-01-18 Monsanto Company Method for producing synthetic N-linked glycoconjugates
JPH09501044A (ja) 1993-05-14 1997-02-04 ジ・アップジョン・カンパニー UDP−GALNAc:ポリペプチド、N−アセチルガラクトサミニルトランスフェラーゼをコードするクローン化されたDNA
US6365723B1 (en) * 1998-12-04 2002-04-02 Wisconsin Alumni Research Foundation Sequences of E. coli O157
US6503744B1 (en) 1999-02-01 2003-01-07 National Research Council Of Canada Campylobacter glycosyltransferases for biosynthesis of gangliosides and ganglioside mimics
EP1399538A4 (en) 1999-03-02 2004-03-24 Human Genome Sciences Inc TECHOLOGICAL MANIPULATION OF INTRACELLULAR SIALIZATION PATHS
JP2004528001A (ja) 2000-05-12 2004-09-16 ネオーズ テクノロジーズ, インコーポレイテッド インビトロにおけるフコシル化組換えグリコペプチド
EP1294910B1 (en) 2000-06-30 2008-11-19 VIB vzw Protein glycosylation modification in pichia pastoris
US20040067557A1 (en) * 2000-12-21 2004-04-08 Tetsuo Endo Process for producing udp-n-acetylgalactosamine and sacciiaride containing n-acetylgalactosamine
US20020132320A1 (en) * 2001-01-10 2002-09-19 Wang Peng George Glycoconjugate synthesis using a pathway-engineered organism
US20020150968A1 (en) * 2001-01-10 2002-10-17 Wang Peng G. Glycoconjugate and sugar nucleotide synthesis using solid supports
US6696814B2 (en) 2001-07-09 2004-02-24 Tyco Electronics Corporation Microprocessor for controlling the speed and frequency of a motor shaft in a power tool
US7265085B2 (en) * 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
US7541043B2 (en) * 2002-01-16 2009-06-02 The United States Of America As Represented By The Department Of Health And Human Services Vaccine for protection against Shigella sonnei disease
IL163806A0 (en) 2002-03-07 2005-12-18 Eidgenoess Tech Hochschule System and method for the production of recombinant glycosylated proteins in a prokaryotic host
KR101495616B1 (ko) * 2002-03-07 2015-02-26 아이드게노쉬쉐 테흐니쉐 호흐슐레 쥬리히 원핵 숙주에서의 재조합 글리코실화 단백질 생산 방법 및 생산계
WO2004013151A2 (en) 2002-08-01 2004-02-12 National Research Council Of Canada Campylobacter glycans and glycopeptides
EP1756149B1 (en) 2004-05-24 2013-09-04 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Live, oral vaccine for protection against shigella dysenteriae serotype 1
US20100143969A1 (en) * 2005-03-24 2010-06-10 Neose Technologies, Inc. Expression of soluble, active eukaryotic glycosyltransferases in prokaryotic organisms
ES2353814T3 (es) * 2005-05-11 2011-03-07 Eth Zuerich Proteinas n-glicosiladas recombinantes de celulas procariotas.
US20070202578A1 (en) * 2005-08-26 2007-08-30 Centre National De La Recherche Scientifique (Cnrs) Production of globosides oligosaccharides using metabolically engineered microorganisms
CN107119095B (zh) * 2008-01-03 2022-07-05 康乃尔研究基金会有限公司 原核生物中的糖基化蛋白表达
CA2711503A1 (en) * 2008-01-08 2009-07-16 Biogenerix Ag Glycoconjugation of polypeptides using oligosaccharyltransferases
CN101983070B (zh) * 2008-02-20 2016-03-30 格林考瓦因有限公司 由来源于原核细胞的重组n-糖基化蛋白制备生物共轭物
PL2411503T3 (pl) * 2009-03-27 2018-01-31 Eidgenoessische Technische Hochschule Zuerich Salmonella enterica prezentująca n-glikan z c. jejuni lub jego pochodne
GB0915403D0 (en) * 2009-09-04 2009-10-07 London School Hygiene & Tropical Medicine Protein glycosylation
NO2501406T3 (https=) * 2009-11-19 2018-05-19
PT2545081E (pt) * 2010-02-11 2015-05-18 Univ Alberta Compostos de glicano ligados por n
EP3281639B1 (en) * 2010-05-06 2020-11-11 GlaxoSmithKline Biologicals S.A. Capsular gram-positive bacteria bioconjugate vaccines
US20130266604A1 (en) * 2010-09-03 2013-10-10 The Governors of the University of Alberta a non-profit educational institution Peptide containing multiple n-linked glycosylation sequons
US8846373B2 (en) * 2011-07-29 2014-09-30 The University Of Wyoming Methods of using a bacterial GlcNAc-6-P 2′- epimerase to promote sialylation of glycoconjugates
US20140336366A1 (en) * 2011-09-06 2014-11-13 Glycovaxyn Ag Bioconjugate vaccines made in prokaryotic cells
EP3508579B1 (en) * 2012-11-07 2021-06-30 GlaxoSmithKline Biologicals SA Production of recombinant vaccine in e. coli by enzymatic conjugation
GB201301085D0 (en) * 2013-01-22 2013-03-06 London School Hygiene & Tropical Medicine Glycoconjugate Vaccine

Also Published As

Publication number Publication date
JP2017018098A (ja) 2017-01-26
KR101855380B1 (ko) 2018-05-08
CN102724997A (zh) 2012-10-10
EP2501406B1 (en) 2017-12-20
IL219733A (en) 2017-08-31
HUE038456T2 (hu) 2018-10-29
EP2501406A1 (en) 2012-09-26
PT2501406T (pt) 2018-02-21
EP2501406B8 (en) 2018-01-24
KR20120102086A (ko) 2012-09-17
ES2660227T3 (es) 2018-03-21
CN102724997B (zh) 2016-09-21
EP2501406A4 (en) 2013-04-24
DK2501406T3 (en) 2018-02-26
CY1119995T1 (el) 2018-12-12
IL219733A0 (en) 2012-07-31
JP5968784B2 (ja) 2016-08-10
US8846342B2 (en) 2014-09-30
US20150190492A1 (en) 2015-07-09
AU2010322454A1 (en) 2012-06-07
AU2010322454B2 (en) 2016-05-19
NO2501406T3 (https=) 2018-05-19
CA2780487C (en) 2019-05-21
CA2780487A1 (en) 2011-05-26
HRP20180338T1 (hr) 2018-04-06
TR201803015T4 (tr) 2018-03-21
SI2501406T1 (en) 2018-03-30
WO2011062615A1 (en) 2011-05-26
US20130028926A1 (en) 2013-01-31
JP2013511520A (ja) 2013-04-04
US9764018B2 (en) 2017-09-19
LT2501406T (lt) 2018-03-26

Similar Documents

Publication Publication Date Title
IL219733A0 (en) Biosynthetic system that produces immunogenic polysaccharides in prokaryotic cells
EG27169A (en) Solar generation method and system
GB2528216B (en) Enhancing residual performance in an energy storage system
GB2508311B (en) Power Connector System
GB2476723B (en) Wind power generation system
ZA201109366B (en) Pure peg-lipid conjugates
EP2494189A4 (en) WIND ENERGY SYSTEM
IL220073A0 (en) Parabolic collector
GB2484619B (en) Power generation system
ZA201007148B (en) Wind energy system comprising busbars
EP2516844A4 (en) ENERGY GENERATION SYSTEM AND RELATED METHODS
EP2413019A4 (en) SOLAR SIMULATOR WITH VARIABLE SPECTRUM
ZA201105576B (en) Improvements in fuels
GB0922067D0 (en) Improvements in vertical axis wind turbines
EP2646679A4 (en) Improvements in turbines
GB0918757D0 (en) Improvements in headwear
GB0911975D0 (en) Energy converting system
IL209762A0 (en) Solar powere 3d glasses
GB2474677B (en) Mail collector
HU0900023D0 (en) Solar system which rotates in vertical plane
AU2010901642A0 (en) Improvements in wave energy extraction systems
AU2010900844A0 (en) Improvements in wave energy extraction systems
TWI365574B (en) Cell connector
GB0906992D0 (en) Cells, preparation, uses, methods and components
AU2009905936A0 (en) Improvements in turbines